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THE MODERA TEL Y difficult model of hamster to rat 
xenotransplantation has been used by many investi-
gators to study the effects of different immunosuppressive 
regimens. I- 3 Our previous studies have shown that with-
out treatment the graft survival times in this xenotrans-
plant model were 3 days. 6 days. and 7 days for heart. 
kidney, and liver xenografts, respectively.l-4 We and 
others have also shown that in this model heart and kidney 
xenografts were rejected mainly by the humoral factors 
whereas the liver was rejected by a mixture of cellular and 
humoral factors. l-4 There are two known mechanisms 
whereby humoral factors can facilitate the destruction of 
xenografts. namely C' -dependent Ab-mediated cytotoxic-
ity (CDC) and Ab-dependent cell-mediated cytotoxicity 
(ADCC). 1.5 The purpose of this study was to analyze the 
induction of humoral. factors after heart. kidney. and liver 
xenotransplantations using hamster aonic endothelial cells 
(AEC) as targets for CDC and ADCC assays rather than 
the conventional lymphocyte targets. 
MATERIALS AND METHODS 
Methods for organ transplantation.Z--4 isolation. and culture of 
AEC· have been described previously. The medium used for AEC 
cultures was DMEM/FI2 containing 5% to 10% hamster serum. 
~fCr release assay7 was used to measure the cytotoxic humoral 
factors against AEC (2 hours for CDC. 4 hours for ADCC). The 
ADCC was expressed as the difference between percent specific 
release in the presence of serum and effector cells and percent 
specific release in serum alone. 
RESULTS AND DISCUSSION 
Histologic study of xenograft rejection indicates that the 
vascular endothelial cell (VEC) is a major target for 
cytotoxic humoral factors in xenograft rejection.1! In vitro 
studies have also shown that the VEC is central to xeno-
geneic immune reactivity.s Therefore. the conventional 
method using lymphocytes as targets for measuring cyto-
toxic serum factors may not be as relevant as using VEC as 
targets. Table 1 shows the kinetics of CDC and ADCC Ab 
induction after xenografting. using hamster AEC as target 
cells. The pretransplant (tx) rat sera contained a small 
amount of natural Ab against hamster AEC in the CDC 
assay. the titer disappearing after 1 :40 dilution. The same 
serum did not facilitate the target cell killing in the AOCC 
assay. since killing by effector cells alone was 10.1 :t 2.1 % 
(Mean :t SEM of five experiments). For heart and kidney 
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Table 1. Destruction of AEC by Humoral Factors Obtained From Xenograft Recipients 
Percent Specdlc Release at Various Serum Dilutions· 
Sera Assay 1:10 1:20 1:40 1:80 1:160 1:320 1:640 
Pre-Tx CDC 14.3::!: 7.8 2.9::!: 2.1 0 0 0 0 
ADCC 6.1 ::!: 2.7 5.9::!: 1.5 6.8:!: 1.1 7.3:!: 0.9 7.8:!: 1.1 8::!: 0.7 
HTD2 CDC 56.8::!: 12.6 48.2:!: 3 29.2:!: 9.4 17.1 :!: 11.9 11.6 :!: 11.3 5.8:!: 4.6 
ADCC 7.6::!: 1.1 6:!: 0.2 3.1 :!: 1.1 2.3:!: 0.6 2::!: 0.6 1.3:!: 0.5 
HTD3 CDC 68.3::!: 3.7 64.7::!: 7.7 6O.2:!: 6.6 50::!: 8.5 48.2:!: 9.7 38.8 :!: 12.8 
ADCC 53.7::!: 27 36.5:!: 12.6 20.8:!: 0.8 12.1 :!: 3.7 8.4 :!: 3.6 4.3:!: 0.1 
KTD3 CDC 51.8 = 8.6 40.3:!: 7 21.8::!: 0.9 14.7=8.3 3.3:!: 4 0.7:!: 0.8 
ADCC 15.2 = 1.6 10.8 = 0.1 10.4:!: 2.1 9.9 :!: 4.1 10.1 = 4.7 10.3:!: 5.6 
KTD5 CDC 39.7 :!: 15.1 55.2:!: 12.7 61.1 :!: 11.9 63 :!: 13 60:!: 12.3 53.4 :!: 17.1 
ADCC 42.5:!: 9.8 32.8 :!: 11.7 22.9:!: 7.5 20:!: 7.2 17.6:!: 6.2 15:!: 4.9 
LTD3 CDC 30.2:!: 12 25.5 :!: 12.7 21.1 :!: 13 17.3:!: 5.7 14.7:!: 12.9 11.3 :!: 11.3 
ADCC 4.9:!: 2.3 7.4:!: 3 8.5:!: 3.9 8.7:!: 4 8.8:!: 4.6 7.8:!: 2 
LTD5 CDC 74.6:!: 12.8 75.9:!: 10.5 76.6:!: 10.3 73.9:!: 9.8 68.1 :!: 7.6 65.1 :!: 7.3 
ADCC 8.5:!: 1.7 13.1 :!: 6.9 13.9:!: 7.8 10.4 :!: 5 12.6:!: 7.3 11.2:!: 6.3 
LTD7 CDC 47.1 :!: 5 49.3:!: 3.9 47.4 :!: 6.9 48.3:!: 7.9 45.9:!: 9.4 40.3 = 6.6 
ADCC 20.6:!: 9.3 24.3:!: 13 26:!: 13.8 26.7:!: 15.3 25.1 :!: 14.7 17:!: 7.9 
'Mean :!: SEM ot three expenments. 
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xenografis. CDC Abs in the sera gradually increased and 
peaked before the grafts were rejected. However. in liver 
xenograft the titer of CDC Ab increased until 5 to 6 days 
post-tx: then the titer dropped before the graft was re-
jected. suggesting that most of the anti-VEC Abs probably 
had already adsorbed to VEC in vivo. It is of interest to 
note that the same sera did not show the reduction in Ab 
titer on day 7 post-tx when lymphocytes were used as 
targets for the CDC assay (data not shown). This finding 
confinns the notion that Ags presented on AEC and Ags 
on lymphocytes that are recognized by the same sera are 
not identical. 5.9 The Ab mediating CDC can be dissociated 
by addition of dithiothreitol. indicating the Ab is of IgM 
isotype (data not shown). 10 
Although all three xenografts induced a high titer of 
CDC Ab against AEC. the same sera were found to be 
ineffective in the ADCC assay. Results in Table I show 
that only day-3 sera after heart tx and day-5 sera after 
kidney tx mediate some measurable amount of cytotoxic-
ity. Day-5 sera from liver tx mediated the highest level of 
CDC; however. the same sera had no effect in the ADCC 
assay. suggesting that these two mechanisms of killing are 
mediated by different Ab. In conclusion. we have demon-
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strated that cytotoxic humoral factors against AEC were 
induced after xenotransplantation in this model. 
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